Singapore Markets open in 4 hrs 38 mins

Global Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Clinical Trials Market Report, H2 2021 Review - ResearchAndMarkets.com

·3-min read

DUBLIN, December 02, 2021--(BUSINESS WIRE)--The "Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

The report provides an overview of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) clinical trials scenario. This report provides top line data relating to the clinical trials on Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency).

Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope

  • The report provides a snapshot of the global clinical trials landscape

  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

  • The Report provides enrollment trends for the past five years

  • Report provides latest news for the past three months

Key Topics Covered:

  • Report Guidance

  • Clinical Trials Report Coverage

  • Clinical Trials by Region

  • Clinical Trials and Average Enrollment by Country

  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific

  • Top Five Countries Contributing to Clinical Trials in Europe

  • Top Countries Contributing to Clinical Trials in North America

  • Top Countries Contributing to Clinical Trials in Middle East and Africa

  • Top Countries Contributing to Clinical Trials in Central and South America

  • Clinical Trials by G7 Countries: Proportion of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) to Immunology Clinical Trials

  • Clinical Trials by Phase in G7 Countries

  • Clinical Trials in G7 Countries by Trial Status

  • Clinical Trials by E7 Countries: Proportion of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) to Immunology Clinical Trials

  • Clinical Trials by Phase in E7 Countries

  • Clinical Trials in E7 Countries by Trial Status

  • Clinical Trials by Phase

  • In Progress Trials by Phase

  • Clinical Trials by Trial Status

  • Clinical Trials by End Point Status

  • Subjects Recruited Over a Period of Time

  • Clinical Trials by Sponsor Type

  • Prominent Sponsors

  • Top Companies Participating in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials

  • Prominent Drugs

  • Clinical Trial Profile Snapshots

  • Appendix

Companies Mentioned

  • Takeda Pharmaceutical Co Ltd

  • BioCryst Pharmaceuticals Inc

  • Pharming Group NV

  • CSL Ltd

  • Kalvista Pharmaceuticals Inc

  • Pharvaris BV

  • Watch Bidco Ltd

  • Ionis Pharmaceuticals Inc

  • Advanced Medical Services GmbH

  • AMS Advanced Medical Services GmbH

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/dnttgp

View source version on businesswire.com: https://www.businesswire.com/news/home/20211202005781/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting